Results 171 to 180 of about 80,978 (300)

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean, Maryam Yazdanfar, Joseph Zepeda, Isha J. Patel, Cynthia Levy, Craig Lammert, Raghav Bordia, Duru Cosar, Katherine Specht, Daniel Pratt, Stuart C. Gordon, Lisa Forman, Fawzy Barry, Michael Li, Usha Gungabissoon, Megan M. McLaughlin, Christopher L. Bowlus   +16 more
wiley   +1 more source

Ultra-rapid outpatient treatment of patients with severe aortic stenosis presenting with acute valve syndrome: evaluation of a novel pathway for urgent TAVI. [PDF]

Open Heart
Vibhishanan J, Winn K, Ferreira-Martins J, Sharma H, Hosin A, Konstanciak K, Matos Dias J, Gurreiro De Almeida J, Hundertmark C, Bulman S, Fullerton JN, Dawkins S, Franks R, Kharbanda RK, Newton JD, Banning AP, Cahill TJ.   +16 more
europepmc   +1 more source

HLA‐A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection

Alimentary Pharmacology &Therapeutics, EarlyView.
The HLA‐A*11:01 allele is associated with persistent viraemia and advanced liver fibrosis in HDV infection. HLA‐A*11:01 carriers exhibit a reduced T‐cell repertoire, suggesting a narrower T‐cell response to the infection. ABSTRACT Background Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous ...
Maria Francesca Cortese, Adriana Palom, Ariadna Rando Segura, Francesc Rudilla, Emma Enrich Rande, Arnau Puig Lopez, David Tabernero Caellas, Judit Vico Romero, Juan Carlos Ruiz‐Cobo, Mar Riveiro‐Barciela, Maria José Herrero, Maria Buti   +11 more
wiley   +1 more source

Bioimpedance Analysis to Predict Clinical Outcomes of Liver Cirrhosis in a Prospective Cohort Study. [PDF]

JGH Open
Kanan M, Luster M, Khaderi S, Kanwal F, Thrift AP, Alsarraj A, Sorial E, Salem E, Duong H, El-Serag HB.   +9 more
europepmc   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet, Elisabetta Degasperi, Annarosa Cussigh, Elisabetta Fontanini, Maria Paola Anolli, Floriana Facchetti, Riccardo Perbellini, Dana Sambarino, Sara Uceda Renteria, Mariapaola Callegaro, Davide Bitetto, Elisa Fumolo, Ezio Fornasiere, Elena Garlatti Costa, Edmondo Falleti, Pietro Lampertico, Pierluigi Toniutto   +16 more
wiley   +1 more source

Epidemiology of Patients With Chronic Liver Disease Presenting to Emergency Departments in Australia. [PDF]

Emerg Med Australas
Latona A, Stuart K, Valery P, Ho A, Mitra B.   +4 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Integrating innovative sensors

International Journal of Integrated Care, 2012
Jennifer Caffarel, Axel Saalbach, Alberto Bonomi, Joerg Habetha, Matthew Harris, Patrik Schauerte, Juan Perez Villacastin, Ramon Bover, Christian Zugck, Juergen Vogt, Arcadi García Alberola, John Cleland   +11 more
doaj   +3 more sources

DYSBIOSIS IN ACUTE-ON-CHRONIC LIVER FAILURE - FROM A PATHOPHYSIOLOGICAL COMPONENT TO A THERAPEUTIC TARGET. [PDF]

Arq Gastroenterol
Mattos AA, Alves CA, Acuña J, Mattos AZ.   +3 more
europepmc   +1 more source

Ropeginterferon‐α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pegylated interferon‐α2a became the off‐label alternative for treating mycosis fungoides/Sézary syndrome (MF/SS) after non‐pegylated interferons were withdrawn. This study aimed to evaluate the safety and efficacy of ropeginterferon‐α2b in MF/SS. Patients and methods We performed a retrospective multicenter analysis at
Stefanie Porkert, Juliette M. Kersten, Rosanne Ottevanger, Hanna Schratter, Regina Fink‐Puches, Van Anh Nguyen, Farzaneh Sadeghyar, Johanna Latzka, Franz Trautinger, Magdalena Hoellwerth, Peter Koelblinger, Nicole Pfannschmidt, Nina Haering, Johannes Griss, Maarten H. Vermeer, Constanze Jonak   +15 more
wiley   +1 more source